摘要
目的:探讨帕金森病并轻度认知功能障碍(PD-MCI)患者血清胱抑素C(Cys-C)水平及其临床意义。方法:选择2014年1月-2017年6月于赣南医学院第一附属医院神经内科住院的120例PD患者,作为PD组,同期选择来院的功能性疾病患者108例为对照组,根据认知功能评定量表将PD组分为3个亚组:PD不伴认知功能障碍(PD-NCI)组42例、PD-MCI组56例和PD伴痴呆(PD-D)组22例。应用免疫比浊法检测血清Cys-C水平。比较PD组及各亚组与对照组血清Cys-C水平的差异;同时比较PD-MCI亚组中不同认知损害的血清Cys-C水平。结果:PD组、PD-MCI组及PD-D组的血清Cys-C水平均显著高于对照组,差异均有统计学意义(P<0.05);PD-NCI组血清Cys-C水平稍高于对照组,但差异无统计学意义(P>0.05);PD-MCI中不同认知损害组的血清Cys-C水平比较,差异无统计学意义(P>0.05)。结论:PD患者血清Cys-C水平升高,在PD-MCI时血清Cys-C水平即升高明显,不同认知功能损害区域血清Cys-C水平无差异,血清Cys-C水平可作为PD认知功能发生发展及病情监测的参考指标。
Objective:To investigate the clinical significance of serum cystatin C(Cys-C)level in Parkinson’s disease with mild cognitive impairment(PD-MCI).Method:A total of 120 patients with Parkinson’s disease(PD)were enrolled from January 2014 to June 2017,as the PD group,at the same time,108 patients with functional diseases as the control group.The PD group was divided into three subgroups according to the cognitive function rating scale:PD with no cognitive impairment(PD-NCI)group 42 cases,PD-MCI group of 56 cases and PD with dementia(PD-D)group of 22 cases.Serum Cys-C levels were measured by immunoturbidimetry.The differences of serum Cys-C levels among PD group,each subgroup and control group were compared.The levels of serum Cys-C in PD-MCI subgroups were compared.Result:The serum Cys-C levels in PD group,PD-MCI group and PD-D group were significantly higher than those in the control group,the differences were statistically significant(P<0.05).The serum Cys-C level in PD-NCI group was slightly higher than that in control group,but there was no significant difference between the two groups(P>0.05).There was no significant difference between PD-MCI and different cognitive impairment groups(P>0.05).Conclusion:Serum Cys-C levels are elevated in patients with Parkinson’s disease,serum Cys-C level is significantly increased in PD-MCI,and there is no difference in serum Cys-C level between different cognitive impairment areas,serum Cys-C level can be used as a reference index for PD cognitive function development and disease monitoring.
作者
朱海兵
欧阳桂兰
赖燕蔚
钟善全
ZHU Haibing;OUYANG Guilan;LAI Yanwei(The First Affiliated Hospital of Gannan Medical University,Ganzhou 341000,China)
出处
《中国医学创新》
CAS
2018年第35期123-126,共4页
Medical Innovation of China
基金
江西省卫生计生委科技计划课题(20165345)
赣州市指导性科技计划课题(GZ2015ZSF053)
